去纤维钠（去纤苷）上市了吗？

(Defibrinoside) is a mixture of single-stranded oligonucleotides with antithrombotic and profibrinolytic effects, indicated for the treatment of severe veno-occlusive disease (VOD) in adults and children who have received chemotherapy and stem cell transplantation. It can increase fibrin lysis and modulate platelet activity to reduce procoagulant activity. It has not been reported to increase the risk of bleeding.

Some foreign researchers first reported the efficacy and prognosis of clinical application of defibrinated sodium in the United States. The results showed that the drug significantly improved the patient's prognosis and survival time. Over time, multiple studies have been reported to confirm the effectiveness of defibrotide sodium in HVOD, including a multi-center clinical study in Europe that showed that 55% of patients were in complete remission; 439 patients were alive after 100 days of treatment.

Since Defitelio has been shown to be effective in clinical trials, is it on the market?

Yes, defibrotide sodium (defibrinoside) is already on the market abroad. On October 18, 2013, defibrotide sodium (defibrotide) was approved for marketing by the EU EMA and received orphan drug designation; on March 30, 2016, the drug was officially approved by the US FDA for marketing. So far, the drug has not been approved for domestic marketing, but patients are also very concerned about its price.

It is understood that a box of 200mg defibrinated sodium sells for around $21,600. Although Defitelio sold abroad is expensive, due to the fact that the drug has not yet been launched in China and there are no generic substitutes, patients can only buy it selectively based on their needs.

Due to exchange rate fluctuations, drug prices will change, so you need to consult Medical Companions for specific prices. At the same time, if patients need it, they can also contact Medical Companion Travel to obtain their drug purchase channels, allowing patients to get what they need more conveniently.

Recommended hot articles: /newsDetail/78616.html